A Study to Learn About How Different Forms of Study Medicine Prifetrastat Are Taken Up Into the Blood in Healthy Adults

← catalyst calendar

NCT07721402 · readout in 111 d

Sponsored by Pfizer (industry) · PFE — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Basic science

Enrollment

32estimated

Sites

Country

Belgium

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-07-14

actual

When the study began enrolling

Primary completion

2026-12-08

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-08

estimated

The whole study's end, after follow-up

First posted

2026-07-23

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Participant

Interventions

Drug: prifetrastat Reference
Drug: prifetrastat Test 1
Drug: prifetrastat Test 2

Primary outcomes

what the primary-completion date above is the date OF

Area under the Plasma Concentration-Time profile from time 0 to extrapolated infinite time (AUCinf) of Reference treatment of prifetrastat (AUClast If data does not permit AUCinf)